An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Canagliflozin (TA-7284) as add-on to GLP-1 Analogue in Subjects With Type 2 Diabetes Mellitus

Trial Profile

An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Canagliflozin (TA-7284) as add-on to GLP-1 Analogue in Subjects With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Jul 2016

At a glance

  • Drugs Canagliflozin (Primary) ; Glucagon like peptide 1 receptor agonists
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 02 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top